Free Trial
NASDAQ:LENZ

LENZ Therapeutics Q2 2025 Earnings Report

LENZ Therapeutics logo
$41.30 +0.49 (+1.21%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

LENZ Therapeutics EPS Results

Actual EPS
-$0.53
Consensus EPS
-$0.58
Beat/Miss
Beat by +$0.05
One Year Ago EPS
N/A

LENZ Therapeutics Revenue Results

Actual Revenue
$5.00 million
Expected Revenue
$5.00 million
Beat/Miss
Met Expectations
YoY Revenue Growth
N/A

LENZ Therapeutics Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Wednesday, July 30, 2025
Conference Call Time
8:00AM ET

Upcoming Earnings

LENZ Therapeutics' Q3 2025 earnings is scheduled for Wednesday, November 5, 2025, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

LENZ Therapeutics Earnings Headlines

$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.tc pixel
LENZ Therapeutics to Present at Upcoming Investor and Medical Conferences
See More LENZ Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like LENZ Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on LENZ Therapeutics and other key companies, straight to your email.

About LENZ Therapeutics

LENZ Therapeutics (NASDAQ:LENZ), a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

View LENZ Therapeutics Profile

More Earnings Resources from MarketBeat